Literature DB >> 7883971

Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity.

C R Pullinger1, L K Hennessy, J E Chatterton, W Liu, J A Love, C M Mendel, P H Frost, M J Malloy, V N Schumaker, J P Kane.   

Abstract

Detection of new ligand-defective mutations of apolipoprotein B (apoB) will enable identification of sequences involved in binding to the LDL receptor. Genomic DNA from patients attending a lipid clinic was screened by single-strand conformation polymorphism analysis for novel mutations in the putative LDL receptor-binding domain of apoB-100. A 46-yr-old woman of Celtic and Native American ancestry with primary hypercholesterolemia (total cholesterol [TC] 343 mg/dl; LDL cholesterol [LDL-C] 241 mg/dl) and pronounced peripheral vascular disease was found to be heterozygous for a novel Arg3531-->Cys mutation, caused by a C-->T transition at nucleotide 10800. One unrelated 59-yr-old man of Italian ancestry was found with the same mutation after screening 1,560 individuals. He had coronary heart disease, a TC of 310 mg/dl, and an LDL-C of 212 mg/dl. A total of eight individuals were found with the defect in the families of the two patients. They had an age- and sex-adjusted TC of 240 +/- 14 mg/dl and LDL-C of 169 +/- 10 mg/dl. This compares with eight unaffected family members with age- and sex-adjusted TC of 185 +/- 12 mg/dl and LDL-C of 124 +/- 12 mg/dl. In a dual-label fibroblast binding assay, LDL from the eight subjects with the mutation had an affinity for the LDL receptor that was 63% that of control LDL. LDL from eight unaffected family members had an affinity of 91%. By way of comparison, LDL from six patients heterozygous for the Arg3500-->Gln mutation had an affinity of 36%. The percentage mass ratio of the defective Cys3531 LDL to normal LDL was 59:41, as determined using the mAb MB19 and dynamic laser light scattering. Thus, the defective LDL had accumulated in the plasma of these patients. Using this mass ratio, it was calculated that the defective Cys3531 LDL particles bound with 27% of normal affinity. Deduced haplotypes using 10 apoB gene markers showed the Arg3531-->Cys alleles to be different in the two kindreds and indicates that the mutations arose independently. The Arg3531-->Cys mutation is the second reported cause of familial ligand-defective apoB.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7883971      PMCID: PMC441461          DOI: 10.1172/JCI117772

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  Monoclonal antibody MB19 detects genetic polymorphism in human apolipoprotein B.

Authors:  S G Young; S J Bertics; L K Curtiss; D C Casal; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

2.  In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia.

Authors:  G L Vega; S M Grundy
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

3.  Familial defective apolipoprotein B-100: enhanced binding of monoclonal antibody MB47 to abnormal low density lipoproteins.

Authors:  K H Weisgraber; T L Innerarity; Y M Newhouse; S G Young; K S Arnold; R M Krauss; G L Vega; S M Grundy; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations.

Authors:  D W Bilheimer; S Eisenberg; R I Levy
Journal:  Biochim Biophys Acta       Date:  1972-02-21

5.  Human LDL receptor gene: HincII polymorphism detected by gene amplification.

Authors:  E Leitersdorf; H H Hobbs
Journal:  Nucleic Acids Res       Date:  1988-07-25       Impact factor: 16.971

6.  Polymorphic DNA region adjacent to the 5' end of the human insulin gene.

Authors:  G I Bell; J H Karam; W J Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

7.  RFLPs of the LDL-receptor gene: their use in the diagnosis of FH and in evaluation of different levels of gene expression on normal subjects.

Authors:  S Bertolini; D A Coviello; P Masturzo; E Zucchetto; N Elicio; R Balestreri; G Orecchini; S Calandra; S Humphries
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

8.  Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding.

Authors:  T L Innerarity; K H Weisgraber; K S Arnold; R W Mahley; R M Krauss; G L Vega; S M Grundy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

9.  Apolipoprotein B: the Ag(a1/d) immunogenetic polymorphism coincides with a T-to-C substitution at nucleotide 1981, creating an Alu I restriction site.

Authors:  X B Wang; P Schlapfer; Y H Ma; R Bütler; J Elovson; V N Schumaker
Journal:  Arteriosclerosis       Date:  1988 Jul-Aug

10.  Nonsense and missense mutations in hemophilia A: estimate of the relative mutation rate at CG dinucleotides.

Authors:  H Youssoufian; S E Antonarakis; W Bell; A M Griffin; H H Kazazian
Journal:  Am J Hum Genet       Date:  1988-05       Impact factor: 11.025

View more
  34 in total

1.  A multilocus genotyping assay for candidate markers of cardiovascular disease risk.

Authors:  S Cheng; M A Grow; C Pallaud; W Klitz; H A Erlich; S Visvikis; J J Chen; C R Pullinger; M J Malloy; G Siest; J P Kane
Journal:  Genome Res       Date:  1999-10       Impact factor: 9.043

2.  Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.

Authors:  J Boren; I Lee; W Zhu; K Arnold; S Taylor; T L Innerarity
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

3.  Association of CASQ2 polymorphisms with sudden cardiac arrest and heart failure in patients with coronary artery disease.

Authors:  Marwan M Refaat; Bradley E Aouizerat; Clive R Pullinger; Mary Malloy; John Kane; Zian H Tseng
Journal:  Heart Rhythm       Date:  2014-01-17       Impact factor: 6.343

Review 4.  [Laboratory diagnosis in preventive cardiology].

Authors:  M Soufi; B Noll; M Herzum; B Simon; A Steinmetz; B Maisch; J R Schaefer
Journal:  Herz       Date:  1999-02       Impact factor: 1.443

5.  Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrent LDLR mutations.

Authors:  M Chmara; B Wasag; M Zuk; J Kubalska; A Wegrzyn; M Bednarska-Makaruk; E Pronicka; H Wehr; J C Defesche; A Rynkiewicz; J Limon
Journal:  J Appl Genet       Date:  2010       Impact factor: 3.240

6.  Mutations in the low-density-lipoprotein receptor gene in German patients with familial hypercholesterolaemia.

Authors:  N Weiss; G Binder; C Keller
Journal:  J Inherit Metab Dis       Date:  2000-12       Impact factor: 4.982

7.  Impact of 3'UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: a pilot study.

Authors:  Tomás Zambrano; Mario Hiroyuki Hirata; Álvaro Cerda; Egidio L Dorea; Gelba A Pinto; Maria C Gusukuma; Marcelo C Bertolami; Luis A Salazar; Rosario Dominguez Crespo Hirata
Journal:  Int J Clin Exp Med       Date:  2015-04-15

8.  Familial hypercholesterolemia in Morocco: first report of mutations in the LDL receptor gene.

Authors:  Mariame El Messal; Karima Aït Chihab; Rachid Chater; Joan Carles Vallvé; Faïza Bennis; Aïcha Hafidi; Josep Ribalta; Mathilde Varret; Mohammed Loutfi; Jean Pierre Rabès; Anass Kettani; Catherine Boileau; Luis Masana; Ahmed Adlouni
Journal:  J Hum Genet       Date:  2003-03-18       Impact factor: 3.172

9.  Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.

Authors:  Clive R Pullinger; Celeste Eng; Gerald Salen; Sarah Shefer; Ashok K Batta; Sandra K Erickson; Andrea Verhagen; Christopher R Rivera; Sean J Mulvihill; Mary J Malloy; John P Kane
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

10.  Common beta-adrenergic receptor polymorphisms are not associated with risk of sudden cardiac death in patients with coronary artery disease.

Authors:  Zian H Tseng; Bradley E Aouizerat; Ludmila Pawlikowska; Eric Vittinghoff; Feng Lin; Dean Whiteman; Annie Poon; David Herrington; Timothy D Howard; Paul D Varosy; Stephen B Hulley; Mary Malloy; John Kane; Pui-Yan Kwok; Jeffrey E Olgin
Journal:  Heart Rhythm       Date:  2008-03-14       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.